Understanding how some E. coli bacteria resist treatment in urinary tract infections.
Official title: The roles of fosfomycin resistant subpopulations of Escherichia coli in urinary tract infection.
Funded at Vanderbilt University · NIH-10976407 · Data updated 2026-11-12
This study is looking at how some E. coli bacteria become resistant to fosfomycin, a key antibiotic for treating urinary tract infections, to help us find better ways to treat these infections as antibiotic resistance grows.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University NIH-funded |
| Lab location | 1 site (Nashville, UNITED STATES) |
| Project start | August 1, 2023 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $33,762 |
| NIH project number | 5F31AI174488-02 |
| Project ID | NIH-10976407 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals experiencing recurrent urinary tract infections, especially those who have been treated with fosfomycin.
✕Less likely to help
Patients with UTIs caused by bacteria that are not E. coli or those who do not have recurrent infections may not benefit from this research.
What this research studies
This research investigates the mechanisms by which certain subpopulations of E. coli develop resistance to fosfomycin, a last-resort antibiotic for urinary tract infections (UTIs). The study will analyze how these resistant bacteria can persist in the urinary tract despite antibiotic treatment, potentially leading to more severe infections. By examining the genetic mutations that confer this resistance, the research aims to uncover new insights into bacterial behavior and infection dynamics. Patients may benefit from a better understanding of how UTIs can be treated more effectively in the face of rising antibiotic resistance.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for urinary tract infections, particularly in cases where traditional antibiotics fail.
How similar studies have gone: Previous research has shown that understanding bacterial resistance mechanisms can lead to significant advancements in treatment options, indicating that this approach has potential for success.
Where this research is happening
-
Vanderbilt University
Nashville, United States Active
Researchers
- Principal investigator: Bermudez, Tomas Alexander — Vanderbilt University
- Study coordinator: Bermudez, Tomas Alexander
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.